Morningstar
RecommendedGuide to Asset Flows Open Window IconGuide to Indexes for Fund Management Open Window IconInvestment Analysis Platform for Fund Managers Fund Insights

AXA Framlington Biotech Fund GBP Z Acc

Register to Unlock Ratings
Performance History31/10/2021
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech Fund GBP Z Acc
Fund9.7-6.419.432.73.8
+/-Cat-0.61.5-0.86.86.7
+/-B’mrk-1.4-3.2-0.910.2-1.2
 
Category: Sector Equity Biotechnology
Category Benchmark: NASDAQ Biotechnology TR USD
Key Stats
NAV
01/12/2021		 GBX 490.00
Day Change 1.87%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB00B784NS11
Fund Size (Mil)
31/10/2021		 GBP 458.25
Share Class Size (Mil)
01/12/2021		 GBP 352.03
Max Initial Charge -
Ongoing Charge
21/09/2021		  0.83%
Investment Objective: AXA Framlington Biotech Fund GBP Z Acc
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Returns
Trailing Returns (GBP)01/12/2021
YTD3.92
3 Years Annualised13.11
5 Years Annualised11.38
10 Years Annualised*18.91
12 Month Yield 0.00
Management
Manager Name
Start Date
Linden Thomson
05/07/2012
Peter Hughes
01/04/2018
Inception Date
16/04/2012
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  AXA Framlington Biotech Fund GBP Z Acc31/10/2021
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock96.380.0096.38
Bond0.000.000.00
Property0.000.000.00
Cash3.630.013.62
Other0.000.000.00
Top 5 Regions%
United States88.31
Asia - Emerging3.76
Eurozone2.95
Europe - ex Euro2.38
United Kingdom1.65
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Regeneron Pharmaceuticals IncHealthcareHealthcare7.94
Gilead Sciences IncHealthcareHealthcare6.31
Biogen IncHealthcareHealthcare5.17
Moderna IncHealthcareHealthcare4.62
Amgen IncHealthcareHealthcare4.56
Increase Decrease New since last portfolio
AXA Framlington Biotech Fund GBP Z Acc

Related

Economic Insights
13 Questions for: Jupiter's David Lewis
In this series, we ask leading fund managers their views on everything from investment strategies to who they look up to, and which investments they j...
Question mark in neon light
Marina Gerner
Fund Research & Insights
US Value Funds Top Performers for March
US funds that focus on smaller companies, value and recovery stocks dominate the list of March's top gainers, while tech and China funds are laggards
arrows going up
James Gard
Fund Research & Insights
Bond Turmoil Shakes Up Fund Tables
The turbulence in the bond and equity markets has upset the usual order among top and bottom performing funds rated by Morningstar, with tech and Chin...
Gold trophy
James Gard
Fund Research & Insights
Best and Worst Funds in October
Chinese funds topped the performance tables in October while the prospects of another lockdown has weighed heavy on European and UK funds
Trophies wide article 2019
Annalisa Esposito
Fund Research & Insights
Best and Worst Funds in September
Japan focused funds top the performance tables in September, even after the announcement of Prime Minister Abe's retirement, while emerging Europe lag...
New gold trophy trophies article new
Annalisa Esposito
ESG
ESG Equity Funds in the Sell-Off
The first quarter of 2020 is the first time that many sustainable funds have been tested in a bear market. We look at how they held up compared to the...
Wind farms thumbnail new
Annalisa Esposito
Fund Research & Insights
Best and Worst Performing Funds in December
UK smaller companies funds enjoy the Boris bounce in December, while property funds struggle on liquidity fears 
Trophies thumbnail
Annalisa Esposito
Fund Research & Insights
Are Property Funds Holding Too Much Cash?
Direct property funds are sitting on cash levels of up to 30%, but just one fund rebates fees if the buffer gets too big
Office buildings thumbnail
James Gard
Fund Research & Insights
Woodford Crisis Weighs on Fund Sales
Passive fund providers BlackRock and LGIM achieved the greatest sales in the third quarter of the year, as uncertain investors look for protection fro...
Gold and silver coins thumbnail
James Gard
ISA Investing
What ISA Funds Are Millennials and Baby Boomers Buying?
There are similarities in the funds bought by both millennials and baby boomers. While the younger generation take more risk, those nearing retirement...
Young family
David Brenchley
* This share class has performance data calculated prior to the inception date, 2012-04-16. This is based upon a simulated/extended track record, using the track record of AXA Framlington Biotech R Acc (ISIN: GB0031007254), and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement       

The Morningstar Star Rating for Stocks is assigned based on an analyst's estimate of a stocks fair value. It is projection/opinion and not a statement of fact. Morningstar assigns star ratings based on an analyst’s estimate of a stock's fair value. Four components drive the Star Rating: (1) our assessment of the firm’s economic moat, (2) our estimate of the stock’s fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process culminates in a single-point star rating that is updated daily. A 5-star represents a belief that the stock is a good value at its current price; a 1-star stock isn't. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Morningstar Star Rating for Stocks, please visit here

Quantitative Fair Value Estimate represents Morningstar’s estimate of the per share dollar amount that a company’s equity is worth today. The Quantitative Fair Value Estimate is based on a statistical model derived from the Fair Value Estimate Morningstar’s equity analysts assign to companies which includes a financial forecast of the company. The Quantitative Fair Value Estimate is calculated daily. It is a projection/opinion and not a statement of fact. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Quantiative Fair Value Estimate, please visit here

Select Your Site Edition To make sure the site is relevant to you, we need to know if you’re an individual investor or a financial professional.